Research
Hormonal
In the fasted state (low insulin), tirzepatide's GIP receptor agonism stimulates lipolysis (fat breakdown) to release stored energy, counter-regulating insulin's storage signal.
When you are not eating, tirzepatide helps your fat cells release stored fat for energy. This happens because the drug's GIP activity stimulates fat breakdown when insulin is low, ensuring your body can access energy stores during fasting periods.
GoodConditionalHIGH confidence
Tirzepatide and GIP regulate the metabolic fate of glucose... Tirzepatide and GIP improve lipid clearance into adipocytes... Tirzepatide enhances adipocyte lipid efflux when insulin levels are low.
Why this rating
Supported by in vitro human adipocyte data and in vivo mouse models showing lipolytic enzyme regulation.
Source
Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor
Ajit Regmi et al. · Cell Metabolism · 2024
DOI 10.1016/j.cmet.2024.05.010
mechanism_onlyCited 95×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →